ACAD
Acadia Pharmaceuticals Inc (ACAD) Q1 2026 Earnings Call
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q1 2026 Earnings Conference
Acadia Pharmaceuticals Inc (ACAD) Q1 2026 Earnings Announcement
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q1 2026 Earnings Announcement
Acadia Pharmaceuticals Inc (ACAD) Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) FY 2026 Other Release
Acadia Pharmaceuticals Inc (ACAD) Forum
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Forum
Acadia Pharmaceuticals Inc (ACAD) Q4 2025 Earnings Call Transcript
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q4 2025 Earnings Call dated Feb. 25, 2026 Corporate Participants: Al Kildani — Senior Vice…
Acadia Pharmaceuticals Inc (ACAD) Sec Form 8K
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Sec Form 8K
Acadia Pharmaceuticals Inc (ACAD) Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) FY 2026 Management Update
Acadia Pharmaceuticals Inc (ACAD) Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) FY 2026 Other Release
Acadia Pharmaceuticals Inc (ACAD) Sec Form 10K
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Sec Form 10K
Acadia Pharmaceuticals Inc (ACAD) Sec Form 8K
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Sec Form 8K